Migraine - Pipeline Review, H1 2018

  • ID: 4516003
  • Drug Pipelines
  • 220 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Amgen Inc
  • Crossject SA
  • InStar Technologies AS
  • Medy-Tox Inc
  • Q BioMed Inc
  • MORE
Migraine - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H1 2018, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Migraine - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 13, 12, 15, 27, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Amgen Inc
  • Crossject SA
  • InStar Technologies AS
  • Medy-Tox Inc
  • Q BioMed Inc
  • MORE
Introduction

Migraine - Overview

Migraine - Therapeutics Development

Migraine - Therapeutics Assessment

Migraine - Companies Involved in Therapeutics Development

Migraine - Drug Profiles

Migraine - Dormant Projects

Migraine - Discontinued Products

Migraine - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Migraine, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Migraine - Pipeline by 4P Therapeutics LLC, H1 2018

Migraine - Pipeline by Abide Therapeutics Inc, H1 2018

Migraine - Pipeline by Achelios Therapeutics Inc, H1 2018

Migraine - Pipeline by Acorda Therapeutics Inc, H1 2018

Migraine - Pipeline by Alder Biopharmaceuticals Inc, H1 2018

Migraine - Pipeline by Allergan Plc, H1 2018

Migraine - Pipeline by Amgen Inc, H1 2018

Migraine - Pipeline by Aralez Pharmaceuticals Inc, H1 2018

Migraine - Pipeline by Astellas Pharma Inc, H1 2018

Migraine - Pipeline by Avanir Pharmaceuticals Inc, H1 2018

Migraine - Pipeline by Axsome Therapeutics Inc, H1 2018

Migraine - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Migraine - Pipeline by BioHealthonomics Inc, H1 2018

Migraine - Pipeline by Blackthorn Therapeutics Inc, H1 2018

Migraine - Pipeline by Charleston Laboratories Inc, H1 2018

Migraine - Pipeline by Corium International Inc, H1 2018

Migraine - Pipeline by Crossject SA, H1 2018

Migraine - Pipeline by Eli Lilly and Co, H1 2018

Migraine - Pipeline by Heptares Therapeutics Ltd, H1 2018

Migraine - Pipeline by Impel NeuroPharma Inc, H1 2018

Migraine - Pipeline by InKemia IUCT Group SA, H1 2018

Migraine - Pipeline by InStar Technologies AS, H1 2018

Migraine - Pipeline by Insys Therapeutics Inc, H1 2018

Migraine - Pipeline by IntelGenx Corp, H1 2018

Migraine - Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Migraine - Pipeline by Klaria Pharma Holding AB, H1 2018

Migraine - Pipeline by Medy-Tox Inc, H1 2018

Migraine - Pipeline by Merck & Co Inc, H1 2018

Migraine - Pipeline by NAL Pharmaceuticals Ltd, H1 2018

Migraine - Pipeline by Pharmaleads SA, H1 2018

Migraine - Pipeline by Promius Pharma LLC, H1 2018

Migraine - Pipeline by Q BioMed Inc, H1 2018

Migraine - Pipeline by Sarfez Pharmaceuticals Inc, H1 2018

Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, H1 2018

Migraine - Pipeline by Suda Ltd, H1 2018

Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Migraine - Pipeline by TheraJect Inc, H1 2018

Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018

Migraine - Pipeline by Trevena Inc, H1 2018

Migraine - Pipeline by Trigemina Inc, H1 2018

Migraine - Pipeline by TrioxBio Inc, H1 2018

Migraine - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2018

Migraine - Pipeline by Xenon Pharmaceuticals Inc, H1 2018

Migraine - Pipeline by Xoc Pharmaceuticals Inc, H1 2018

Migraine - Pipeline by Zosano Pharma Corp, H1 2018

Migraine - Dormant Projects, H1 2018

Migraine - Dormant Projects, H1 2018 (Contd..1), H1 2018

Migraine - Dormant Projects, H1 2018 (Contd..2), H1 2018

Migraine - Dormant Projects, H1 2018 (Contd..3), H1 2018

Migraine - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Migraine, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4P Therapeutics LLC
  • Abide Therapeutics Inc
  • Achelios Therapeutics Inc
  • Acorda Therapeutics Inc
  • Alder Biopharmaceuticals Inc
  • Allergan Plc
  • Amgen Inc
  • Aralez Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Avanir Pharmaceuticals Inc
  • Axsome Therapeutics Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioHealthonomics Inc
  • Blackthorn Therapeutics Inc
  • Charleston Laboratories Inc
  • Corium International Inc
  • Crossject SA
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • Impel NeuroPharma Inc
  • InKemia IUCT Group SA
  • InStar Technologies AS
  • Insys Therapeutics Inc
  • IntelGenx Corp
  • Ionis Pharmaceuticals Inc
  • Klaria Pharma Holding AB
  • Medy-Tox Inc
  • Merck & Co Inc
  • NAL Pharmaceuticals Ltd
  • Pharmaleads SA
  • Promius Pharma LLC
  • Q BioMed Inc
  • Sarfez Pharmaceuticals Inc
  • Shin Nippon Biomedical Laboratories Ltd
  • Suda Ltd
  • Teva Pharmaceutical Industries Ltd
  • TheraJect Inc
  • Tonix Pharmaceuticals Holding Corp
  • Trevena Inc
  • Trigemina Inc
  • TrioxBio Inc
  • Ultragenyx Pharmaceutical Inc
  • Xenon Pharmaceuticals Inc
  • Xoc Pharmaceuticals Inc
  • Zosano Pharma Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll